Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT00083889

Public ClinicalTrials.gov record NCT00083889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).

Study identification

NCT ID
NCT00083889
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
750 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2004 (Type not available)
Primary completion
Sep 2008 (Actual)
Completion
Sep 2008 (Actual)
Last update posted
Jan 26, 2010

2004 – 2008

United States locations

U.S. sites
58
U.S. states
27
U.S. cities
44
Facility City State ZIP Site status
Pfizer Investigational Site Jonesboro Arkansas 72401 —
Pfizer Investigational Site La Jolla California 92037 —
Pfizer Investigational Site La Jolla California 92093 —
Pfizer Investigational Site Los Angeles California 90095 —
Pfizer Investigational Site San Diego California 92103 —
Pfizer Investigational Site San Francisco California 94115 —
Pfizer Investigational Site Aurora Colorado 80040-0510 —
Pfizer Investigational Site New Haven Connecticut 06504 —
Pfizer Investigational Site New Haven Connecticut 06511 —
Pfizer Investigational Site New Haven Connecticut 06520 —
Pfizer Investigational Site Miami Florida 33136 —
Pfizer Investigational Site Miami Florida 33176 —
Pfizer Investigational Site Tampa Florida 33612 —
Pfizer Investigational Site Chicago Illinois 60611 —
Pfizer Investigational Site Maywood Illinois 60153 —
Pfizer Investigational Site Kansas City Kansas 66112 —
Pfizer Investigational Site Overland Park Kansas 66210 —
Pfizer Investigational Site Louisville Kentucky 40207 —
Pfizer Investigational Site Covington Louisiana 70433 —
Pfizer Investigational Site Metairie Louisiana 70002 —
Pfizer Investigational Site Metairie Louisiana 70006 —
Pfizer Investigational Site Baltimore Maryland 21287 —
Pfizer Investigational Site Boston Massachusetts 02114 —
Pfizer Investigational Site Boston Massachusetts 02115 —
Pfizer Investigational Site Detoit Michigan 48201 —
Pfizer Investigational Site Detroit Michigan 48201 —
Pfizer Investigational Site Farmington Hills Michigan 48334 —
Pfizer Investigational Site Minneapolis Minnesota 55455 —
Pfizer Investigational Site Columbus Mississippi 39705 —
Pfizer Investigational Site Corinth Mississippi 38834 —
Pfizer Investigational Site Jackson Mississippi 39213 —
Pfizer Investigational Site Jackson Mississippi 39216 —
Pfizer Investigational Site Southaven Mississippi 38671 —
Pfizer Investigational Site Tupelo Mississippi 38801 —
Pfizer Investigational Site Kansas City Missouri 64131 —
Pfizer Investigational Site Omaha Nebraska 68198-9200 —
Pfizer Investigational Site Lebanon New Hampshire 03756 —
Pfizer Investigational Site New York New York 10021 —
Pfizer Investigational Site New York New York 10022 —
Pfizer Investigational Site The Bronx New York 10466 —
Pfizer Investigational Site Cleveland Ohio 44106-5055 —
Pfizer Investigational Site Cleveland Ohio 44195 —
Pfizer Investigational Site Tulsa Oklahoma 74104 —
Pfizer Investigational Site Tulsa Oklahoma 74133 —
Pfizer Investigational Site Tulsa Oklahoma 74136 —
Pfizer Investigational Site Portland Oregon 97210 —
Pfizer Investigational Site Portland Oregon 97239 —
Pfizer Investigational Site Philadelphia Pennsylvania 19111-2497 —
Pfizer Investigational Site Memphis Tennessee 38104 —
Pfizer Investigational Site Memphis Tennessee 38120 —
Pfizer Investigational Site Nashville Tennessee 37232 —
Pfizer Investigational Site Dallas Texas 75246 —
Pfizer Investigational Site Houston Texas 77030 —
Pfizer Investigational Site Tyler Texas 75702 —
Pfizer Investigational Site Salt Lake City Utah 84112 —
Pfizer Investigational Site Seattle Washington 98101 —
Pfizer Investigational Site Seattle Washington 98109-1023 —
Pfizer Investigational Site Madison Wisconsin 53792-0001 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00083889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 26, 2010 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00083889 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →